Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry

The Parenteral Drug Association (PDA), a non-profit international professional association of pharmaceutical industry professionals, submitted comments to improve the draft guidance. They advocate for harmonizing the guidance's terminology with International Council for Harmonisation (ICH) standards and suggest specific technical updates regarding impurity definitions and analytical product parameters.

The commenter supports the draft guidance as a necessary step for regulating impurities in fermentation- and semi-synthesis-derived antibiotics but argues that the scope should be expanded. They specifically advocate for including requirements to identify and control "interaction impurities" that occur in combination antibiotic drug products containing multiple active pharmaceutical ingredients.

Jitendra Pund provides a structured breakdown of how manufacturers should approach defining specifications, selecting analytical procedures, and validating methods for drug products. The commenter argues that following these rigorous scientific standards ensures regulatory compliance and safeguards patient health.